"Sharing Expertise" is a promise to customers and colleagues to share medical knowledge and expertise for the benefit of health, to use this knowledge effectively and to expand it logically, consistently and with determination, in dialogue with our partners. The B. Braun brand rests on three supporting pillars: our brand values of innovation, efficiency and sustainability.
Vascular Systems, a subdivision of B. Braun's Aesculap division, created with SeQuent® Please – a clinically proven Drug Eluting Balloon – a true innovation. SeQuent® Please offers cardiologists a new treatment option and patients a safe and effective coronary artery disease therapy.
Thanks to its proven efficacy especially in ISR and SVD SeQuent Please is the perfect product to increase your efficiency.
SeQuent® Please translates sustainability as follows:
SeQuent® Please – a clinically proven drug eluting balloon
SeQuent® Please is a novel concept of targeted, polymerfree and homogenous drug delivery to treat different types of coronary stenosis. It is intended to be used for all common coronary lesions including the ‘worst-case’ indications:
The non-stent based drug delivery using Paclitaxel matrix Drug Eluting Balloons (DEB) have received significant attention based on very favourable DEB outcomes in a number of preclinical and clinical trials.
The initial concept that drug delivery is mediated by the stent struts as the drug carrier and that the drug eluting process requires a longer lasting drug release in the range of weeks are apparently not essential to yield favourable and sustained patient outcomes. Furthermore polymer based drug delivery applied in DES may not be a treatment of choice for all patients that may have anticoagulation therapy compliance issues.
There is growing evidence that Paclitaxel eluting DEB may eliminate factors of incertitude relative to late thrombosis and antiplatelet therapy compliance since there is no polymer implanted into the vascular wall.
PEPCAD Clinical Program
SeQuent® Please has been clinically studied in the PEPCAD (Paclitaxel Eluting PTCA Catheter in Coronary Artery Disease) Clinical Program. The first two trials directed by Martin Unverdorben targeted ‘In Stent Restenosis’ (ISR) and Small Vessel Disease (SVD). The rationale to study stenosis in small vessels (PEPCAD I) of diameters less than 2.8 mm was primarily the fact that these lesions remain to be a challenge for interventionalists even in the DES era.
Since the Paclitaxel PACCOCATH® coating of PTCA catheters lead to a highly significant reduction of Late Lumen Loss in ISR as compared to Plain Old Balloon Angioplasty it was of paramount interest to study the safety and efficacy of SeQuent® Please compared to a widely used Paclitaxel Eluting Stent (PEPCAD II). These two trials are complemented by initiated PEPCAD studies targeting advanced artery disease, chronic total occlusion, diabetic study populations and bifurcation lesions.